Wieland H - Search Results

1

The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction.

Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. Nauck M, et al. Among authors: wieland h. J Mol Med (Berl). 2002 Aug;80(8):507-13. doi: 10.1007/s00109-002-0354-2. Epub 2002 Jun 21. J Mol Med (Berl). 2002. PMID: 12185451

2

C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. Nauck M, et al. Among authors: wieland h. Am J Cardiol. 2002 Dec 1;90(11):1249-52. doi: 10.1016/s0002-9149(02)02845-x. Am J Cardiol. 2002. PMID: 12450609 No abstract available.

3

Rapid, homogeneous genotyping of the 4G/5G polymorphism in the promoter region of the PAII gene by fluorescence resonance energy transfer and probe melting curves.

Nauck M, Wieland H, März W. Nauck M, et al. Among authors: wieland h. Clin Chem. 1999 Aug;45(8 Pt 1):1141-7. Clin Chem. 1999. PMID: 10430777

4

Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes.

Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, März W. Winkler K, et al. Among authors: wieland h. J Clin Endocrinol Metab. 2004 Mar;89(3):1153-9. doi: 10.1210/jc.2003-031494. J Clin Endocrinol Metab. 2004. PMID: 15001601 Clinical Trial.

5

Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study).

Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schäfer G, Seelhorst U, Wellnitz B, Wieland H, Boehm BO, März W. Winkler K, et al. Among authors: wieland h. Clin Chem. 2007 Aug;53(8):1440-7. doi: 10.1373/clinchem.2007.086298. Epub 2007 Jun 15. Clin Chem. 2007. PMID: 17573419

6

Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol.

Nauck M, Winkler K, Wittmann C, Mayer H, Luley C, März W, Wieland H. Nauck M, et al. Among authors: wieland h. Clin Chem. 1995 May;41(5):731-8. Clin Chem. 1995. PMID: 7537187

7

Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia.

Nauck MS, Nissen H, Hoffmann MM, Herwig J, Pullinger CR, Averna M, Geisel J, Wieland H, März W. Nauck MS, et al. Among authors: wieland h. Clin Chem. 1998 Jul;44(7):1388-96. Clin Chem. 1998. PMID: 9665414

8

Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease.

Winkelmann BR, Russ AP, Nauck M, Klein B, Böhm BO, Maier V, Zotz R, Matheis G, Wolf A, Wieland H, Gross W, Galton DJ, März W. Winkelmann BR, et al. Among authors: wieland h. Am Heart J. 1999 Apr;137(4 Pt 1):698-705. doi: 10.1016/s0002-8703(99)70226-7. Am Heart J. 1999. PMID: 10097233

9

Evaluation of the apo E genotyping kit on the LightCycler.

Nauck M, Hoffmann MM, Wieland H, März W. Nauck M, et al. Among authors: wieland h. Clin Chem. 2000 May;46(5):722-4. Clin Chem. 2000. PMID: 10794760 No abstract available.

10

HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?

März W, Wieland H. März W, et al. Among authors: wieland h. Herz. 2000 Mar;25(2):117-25. doi: 10.1007/pl00001949. Herz. 2000. PMID: 10829251 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

284 results

Search Page